MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Key Inclusion Criteria:

• Participant must be ≥ 18 years at the time of screening

• Histologically proven diagnosis of pleural mesothelioma with known histology (epithelioid vs. non-epithelioid)

• Advanced unresectable disease that cannot be treated with curative surgery (with orwithout chemotherapy)

• WHO/ECOG performance status of 0 or 1 with no deterioration (that is, ECOG PS>1)over the previous 2 weeks prior to day of first dosing

• Has measurable disease per modified RECIST1.1

• Has adequate bone marrow reserve and organ function at baseline

Key Exclusion Criteria:

• As judged by the investigator, any condition that would interfere with evaluation ofthe investigational product or interpretation of participant safety or studyresults.

• Active or prior documented autoimmune or inflammatory disorders

• History of another primary malignancy with exceptions.

• Uncontrolled intercurrent illness

• Tuberculosis, hepatitis B (HBV) or hepatitis C (HCV), human immunodeficiency virus (HIV) infection that is not well controlled

• Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonaltherapy for cancer treatment

• Untreated or progressive CNS metastatic disease